IJU case reports · 2025
A Case of Acquired Factor V Deficiency in a Hemodialysis Patient: A Case Report With Literature Review.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sugino Akihiko, Miyazawa Yoshiyuki, Harashima Shugo, Shimizu Yusaku, Kajita Mikiya, Miyazawa Yuri, Ogawa Yoshiyuki, Handa Hiroshi, Sekine Yoshitaka, Suzuki Kazuhiro
Аннотация
INTRODUCTION: Acquired factor V (FV) deficiency is a rare bleeding disorder requiring careful management, especially in hemodialysis (HD) patients who regularly receive anticoagulants. We present a case of recurrent acquired FV deficiency in a dialysis patient.
CASE PRESENTATION: A 76-year-old man on HD with a history of acquired FV deficiency developed third-degree burns and persistent bleeding. Lab tests confirmed the recurrence of the deficiency. Initial treatments with rituximab and cyclophosphamide were ineffective. When prednisolone was rechallenged, the activity of coagulation FV was rapidly improved, and coagulation function was confirmed to have returned to normal. HD was managed without anticoagulants during critical periods. No major bleeding events were observed during HD.
CONCLUSION: This case underscores the complexities of managing acquired FV deficiency in patients on HD. It highlights the importance of individualized anticoagulation strategies and close monitoring of coagulation profiles to prevent bleeding complications and ensure the safety of HD.
CASE PRESENTATION: A 76-year-old man on HD with a history of acquired FV deficiency developed third-degree burns and persistent bleeding. Lab tests confirmed the recurrence of the deficiency. Initial treatments with rituximab and cyclophosphamide were ineffective. When prednisolone was rechallenged, the activity of coagulation FV was rapidly improved, and coagulation function was confirmed to have returned to normal. HD was managed without anticoagulants during critical periods. No major bleeding events were observed during HD.
CONCLUSION: This case underscores the complexities of managing acquired FV deficiency in patients on HD. It highlights the importance of individualized anticoagulation strategies and close monitoring of coagulation profiles to prevent bleeding complications and ensure the safety of HD.